Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Accelerated treatment of endocarditis-The POET II trial: Rationale and design of a randomized controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Validation of the all-comers design: Results of the TARGET-AC substudy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Rationale and design of DanGer shock: Danish-German cardiogenic shock trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Charlson Comorbidity Index Score and Risk of Severe Outcome and Death in Danish COVID-19 Patients

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. Prevalence of Infective Endocarditis in Streptococcal Bloodstream Infections is Dependent on Streptococcal Species

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: The optimal antibiotic treatment length for infective endocarditis (IE) is uncertain. International guidelines recommend treatment duration of up to 6 weeks for patients with left-sided IE but are primarily based on historical data and expert opinion. Efficacies of modern therapies, fast recovery seen in many patients with IE, and complications to long hospital stays challenge the rationale for fixed treatment durations in all patients.

OBJECTIVE: The objective was to conduct a noninferiority randomized controlled trial (acronym POET II) investigating the safety of accelerated (shortened) antibiotic therapy as compared to standard duration in patients with left-sided IE.

METHODS: The POET II trial is a multicenter, multinational, open-label, noninferiority randomized controlled trial. Patients with definite left-sided IE due to Streptococcus spp, Staphylococcus aureus, or Enterococcus faecalis will be eligible for enrolment. Each patient will be randomized to accelerated antibiotic treatment or standard-length treatment (1:1) following clinical stabilization as defined by clinical parameters, laboratory values, and transesophageal echocardiography findings. Accelerated treatment will be between 2 and 4 weeks, whereas standard-length treatment will be between 4 and 6 weeks, depending on microbiologic etiology, complications, need for valve surgery, and prosthetic versus native valve endocarditis. The primary outcome is a composite of all-cause mortality, unplanned cardiac surgery, relapse of bacteremia, or embolization within 6 months of randomization.

CONCLUSIONS: The POET II trial will investigate the safety of accelerated antibiotic therapy for patients with left-sided IE caused by Streptococcus spp, Staphylococcus aureus, or Enterococcus faecalis. The results of the POET II trial will improve the evidence base of treatment recommendations, and clinical practice may be altered.

OriginalsprogEngelsk
TidsskriftAmerican Heart Journal
Vol/bind227
Sider (fra-til)40-46
Antal sider7
ISSN0002-8703
DOI
StatusUdgivet - sep. 2020

Bibliografisk note

Copyright © 2020 Elsevier Inc. All rights reserved.

ID: 60379412